Hormonal therapy for prostate cancer: Current topics and future perspectives: Editorial

International Journal of Urology

Volumn 17, Issue 4, 2010, Pages 302-313

  Suzuki, Hiroyoshi ^d   Hinotsu, Shiro ^a   Akaza, Hideyuki ^b   Fujii, Yasuhisa ^c   Kawakami, Satoru ^c   Kihara, Kazunori ^c   Akakura, Koichiro ^e   Suzuki, Motofumi ^f   Kitamura, Tadaichi ^f   Homma, Yukio ^f   Mizokami, Atsushi ^g  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYTOCHROME P450 1A1; DOCETAXEL; DUTASTERIDE; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN ANTAGONIST; MDV 3100; MICROTUBULE ANTIBODY; PLACEBO; PRASTERONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; RD 162; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; KIDNEY CARCINOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ESTRAMUSTINE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 77949901296     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02460.x     Document Type: Editorial

References (52)

1. Cooperberg MR, Hinotsu S, Namiki M et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J. Clin. Oncol. 2009 27 : 4306 4313.
2. Cooperberg MR, Broering JM, Litwin MS et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J. Urol. 2004 171 : 1393 1401.
3. Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 2005 173 : 1938 1942.
4. Akaza H, Hinotsu S, Usami M et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009 115 : 3437 3445.
5. Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 2009 115 : 3376 3378.
6. Simmons MN, Klein EA. Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer. Urology 2009 73 : 697 705.
7. Palmberg C, Koivisto P, Kakkola L et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol. 2000 164 : 1992 1995.
8. Fowler JE Jr., Pandey P, Seaver LE et al. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J. Urol. 1995 154 : 448 453.
9. Scher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol. 1997 15 : 2928 2938.
10. Joyce R, Fenton MA, Rode P et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol. 1998 159 : 149 153.
11. Fossa SD, Slee PH, Brausi M et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J. Clin. Oncol. 2001 19 : 62 71.
12. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004 63 : 732 736.
13. Fujikawa K, Matsui Y, Fukuzawa S et al. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur. Urol. 2000 37 : 218 222.
14. Kojima S, Suzuki H, Akakura K et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 2004 171 : 679 683.
15. Fujii Y, Kawakami S, Masuda H et al. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int. 2006 97 : 1184 1189.
16. Soga N, Onishi T, Arima K et al. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy. Int. J. Urol. 2007 14 : 192 196 discussion 197.
17. Takeshita H, Kawakami S, Fukui I. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy. Int. J. Urol. 2009 16 : 337 338.
18. Imamoto T, Suzuki H, Yano M et al. The role of testosterone in the pathogenesis of prostate cancer. Int. J. Urol. 2008 15 : 472 480.
19. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355 : 1491 1498.
20. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the FLT withdrawal syndrome. J. Urol. 1993 149 : 607 609.
21. Suzuki H, Okihara K, Miyake H et al. Alternative non-steroidal antiandrogen therapy for advanced prostate cancer that has relapsed after initial maximum androgen blockade. J. Urol. 2008 180 : 921 927.
22. Suzuki H, Ueda T, Ichikawa T et al. Androgen receptor involvement in the progression of prostate cancer. Endocr. Relat. Cancer 2003 10 : 209 216.
23. Terada N, Shimizu Y, Yoshida Y et al. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate 2010 70 : 252 261.
24. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995 46 : 142 148.
25. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993 71 : 2782 2790.
26. Sato N, Akakura K, Isaka S et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004 64 : 341 345.
27. de Leval J, Boca P, Youssef E et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002 1 : 163 171.
28. Schasfoort E, Heathcote P, Lock T et al. Intermittent androgen suppression for the treatment of advanced prostate cancer. J. Urol. 2003 169 (Suppl 1483.
29. Yamanaka H, Ito K, Naito S et al. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate. 2005 63 : 56 64.
30. Miller K, Steiner U, Lingnau A et al. Intermittent versus continuous androgen suppression in advanced prostate cancer-a randomised prospective study. J. Urol. 2007 177 (Suppl 573.
31. Tunn UW, Canepa G, Hillger H et al. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO Study AP 06/95, EC507. J. Urol. 2007 177 (Suppl 201.
32. Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 2006 24 : 3984 3990.
33. Calais da Silva FEC, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur. Urol. 2009 55 : 1269 1277.
34. Salonen AJ, Viitanen J, Lundstedt S et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J. Urol. 2008 180 : 915 920.
35. Shaw GL, Wilson P, Cuzick J et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 2007 99 : 1056 1065.
36. Ideta AM, Tanaka G, Takeuchi T, Aihara K. A mathematical model of intermittent androgen suppression for prostate cancer. J. Nonlinear Sci. 2008 18 : 593 641.
37. Matsumoto A, Inoue A, Yokoi S et al. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int. J. Urol. 2009 16 : 687 691.
38. Fizazi K, Le Maitre A, Hudes G et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007 8 : 944 1000.
39. Kitamura T, Nishimatsu H, Suzuki M et al. Dual interim report of low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. J. Appl. Res. 2005 2 : 331 344.
40. Naiki T, Okamura T, Kawai N et al. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. Asian Pac. J. Cancer Prev. 2009 10 : 71 4.
41. Mamun MRI, Suzuki M, Takahashi S et al. Incidence of gastrointestinal toxicity during estramustine phosphate therapy for prostate cancer is associated with the single-nucleotide polymorphisms in the cytochrome P450 1A1 (CYP1A1) gene. Cancer Ther. 2005 3 : 525 530.
42. Daponte D, Sylvester R, De Pauw M et al. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol. Br. J. Urol. 1983 55 : 408 412.
43. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001 1 : 34 45.
44. Mizokami A, Koh E, Fujita H et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004 64 : 765 771.
45. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 2004 10 : 7121 7126.
46. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract. Res. Clin. Endocrinol. Metab. 2008 22 : 207 221.
47. Uemura M, Tamura K, Chung S et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008 99 : 81 6.
48. Fung KM, Samara EN, Wong C et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr. Relat. Cancer 2006 13 : 169 180.
49. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006 66 : 2815 2825.
50. Mizokami A, Koh E, Izumi K et al. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr. Relat. Cancer 2009 16 : 1139 1155.
51. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 324 : 787 790.
52. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 2009 27 : 3742 3748.